Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Inovio Pharmaceuticals Inc. (NYSE-M:INO) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury